There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > COLUMN
COLUMN
-
Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
-
The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
-
Please Come Back to the Office!
June 24, 2022
-
Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
-
Tapping into One’s Ikigai by Working from Home
May 27, 2022
-
The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
-
Five Ways to Get Your New Hire on the Same Page
March 31, 2022
-
4 Things You Can Do to Overcome Zoom Overload
November 26, 2021
-
What Does a Great Boss Look Like?
October 29, 2021
-
What Is the Price of a Work-Life Balance?
September 24, 2021
-
Obituary: P. Reed Maurer
September 14, 2021
-
Digital and Cultural Transformation in Japanese Pharmaceuticals
August 13, 2021
-
How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
July 13, 2021
-
Does Your Company Want to Increase Its Diversity?
July 5, 2021
-
5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
-
Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
-
Set the Stage for an Exceptional Customer Experience
May 21, 2021
-
Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
-
Do You Attract or Repel Winning Candidates?
April 16, 2021
-
The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…